

# Time-Gated Raman Spectroscopy for Quantitative Determination of Solid-State Forms of Fluorescent Pharmaceuticals

Tiina Lipiäinen,<sup>†,‡</sup> Jenni Pessi,<sup>†,‡</sup> Parisa Movahedi,<sup>‡</sup> Juha Koivistoinen,<sup>§</sup> Lauri Kurki,<sup>||</sup> Mari Tenhunen,<sup>||</sup> Jouko Yliruusi,<sup>†</sup> Anne M. Juppo,<sup>†</sup> Jukka Heikkonen,<sup>‡</sup> Tapio Pahikkala,<sup>‡</sup> and Clare J. Strachan<sup>\*,†</sup>


<sup>†</sup>Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 Helsinki, Finland

<sup>‡</sup>Department of Future Technologies, University of Turku, Vesilinnantie 5, FI-20500 Turku, Finland

<sup>§</sup>Nanoscience Center, Department of Chemistry, University of Jyväskylä, P.O. Box 35, FI-40014, Jyväskylä, Finland

<sup>||</sup>TimeGate Instruments, Teknologiantie 5, FI-90590 Oulu, Finland

## Supporting Information



**ABSTRACT:** Raman spectroscopy is widely used for quantitative pharmaceutical analysis, but a common obstacle to its use is sample fluorescence masking the Raman signal. Time-gating provides an instrument-based method for rejecting fluorescence through temporal resolution of the spectral signal and allows Raman spectra of fluorescent materials to be obtained. An additional practical advantage is that analysis is possible in ambient lighting. This study assesses the efficacy of time-gated Raman spectroscopy for the quantitative measurement of fluorescent pharmaceuticals. Time-gated Raman spectroscopy with a  $128 \times (2) \times 4$  CMOS SPAD detector was applied for quantitative analysis of ternary mixtures of solid-state forms of the model drug, piroxicam (PRX). Partial least-squares (PLS) regression allowed quantification, with Raman-active time domain selection (based on visual inspection) improving performance. Model performance was further improved by using kernel-based regularized least-squares (RLS) regression with greedy feature selection in which the data use in both the Raman shift and time dimensions was statistically optimized. Overall, time-gated Raman spectroscopy, especially with optimized data analysis in both the spectral and time dimensions, shows potential for sensitive and relatively routine quantitative analysis of photoluminescent pharmaceuticals during drug development and manufacturing.

Most (90%) active pharmaceutical ingredients (APIs) crystallize as solid particles.<sup>1</sup> Different inter- and intramolecular bonding and conformations in solid-state forms of a substance, such as polymorphs, amorphous solids, salts, and solvates, result in different physicochemical properties.<sup>2,3</sup> Dissolution rate, solubility, stability, and bioavailability, among other properties, depend on the solid-state structure of the substance. This poses challenges to the pharmaceutical industry in terms of material characterization, formulation, processing, and end product quality control and has therapeutic, legal, and commercial implications.<sup>4</sup>

Effective methods for evaluating the possible changes in solid-state structure during research and development, manufacturing,

and storing are needed.<sup>5,6</sup> Raman spectroscopy is an established method for qualitative and quantitative analysis of APIs exhibiting different solid-state forms and often enables rapid, nondestructive measurements with no sample preparation needed.<sup>7–9</sup> The spectra can be measured through container walls, blisters, plastic bags, and in an aqueous environment because Raman spectroscopy has low sensitivity for water.<sup>10</sup> The form of the sample is also flexible; powders, slurries, pellets, emulsions, and films are all suitable for Raman spectroscopy. These properties

Received: January 19, 2018

Accepted: March 7, 2018

Published: March 7, 2018


make Raman spectroscopy well-suited for diverse real-time process monitoring applications.

Raman spectra are obtained by measuring the intensity distribution of Raman scattered photons from a monochromatic light source as a function of wavelength.<sup>10,11</sup> Quantitative determination is based on the concentration of the substance of interest being proportional to the integrated intensity of its characteristic Raman bands.<sup>12</sup> Overlapping peaks of different compounds in a mixture and experimental effects that are not related to sample concentration complicate the analysis.<sup>13</sup> In such cases, multivariate analysis, where a large amount of spectral data can be included, is more reliable than methods where only one or a few spectral features are considered. Several multivariate methods have been established for the interpretation of Raman spectra.<sup>14,15</sup> The aims of such methods are to (i) extract spectral information that quantifies substances of interest, (ii) estimate the uncertainties of the quantification, and (iii) evaluate the performance of the built model.<sup>14</sup> Partial least-squares (PLS) regression is one of the most widely used chemometric methods for quantitative analysis.<sup>16</sup> PLS relates the information in two data matrices, X (e.g., the spectral variation) and Y (e.g., the sample composition), in a multivariate model by maximizing their covariance.<sup>17</sup> Kernel-based regularized least-squares (kernel-based RLS) regression is another approach that has the ability to learn functions from the nonlinear data features which, when combined with feature selection algorithms such as greedy forward feature selection, optimizes the use of information provided by the data features.<sup>18,19</sup> PLS and RLS are quite similar in that they aim to shrink the solution away from the ordinary least-squares solution toward the directions of the variable space of large sample spread with lower variability.<sup>20</sup>

Error sources in the quantitative analysis of powder mixtures using Raman spectroscopy include intra- and interday variation of the Raman instrument, changes in room temperature and humidity, sample fluorescence, mixing, packing, and positioning, as well as sample particle size and compactness.<sup>21,22</sup> While most issues can be addressed with suitable spectral processing and data analysis approaches, complete subtraction of fluorescence without any instrument-based methods is difficult, even with sophisticated algorithms.<sup>10</sup>

Complete or partial rejection of the fluorescence signal from the Raman signal is possible with various time-resolved techniques.<sup>23</sup> The ability to detect the arrival time and energy of each photon allows assessment of the lifetime of both the fluorescence and Raman signals. Due to the lifetime differences, rejecting the fluorescence background is possible (Figure 1). Time-gated devices employ short, intensive laser pulses and the sample response is recorded simultaneously with the pulses. This also means that analysis in ambient lighting is possible.<sup>24</sup>

Time-gating can be realized with various detection systems such as time-resolved photomultiplier tubes,<sup>26,27</sup> high-speed optical shutters based on a Kerr cells,<sup>28,29</sup> intensified charge-coupled devices,<sup>30</sup> quantum dot resonant tunneling diodes,<sup>31</sup> and complementary metal-oxide semiconductor single-photon avalanche diodes (CMOS SPADs).<sup>24</sup> One of the essential advantages of CMOS SPADs is the ability to reject both the photoluminescence tail and the photon noise.<sup>32</sup> SPADs are realized in standard CMOS technology and contain a pn junction which is reverse-biased above its breakdown voltage, meaning that entry of even a single photon can trigger avalanche breakdown that can then be recorded.<sup>33–35</sup> The width and position of the time gate need to be properly selected.<sup>36</sup>



**Figure 1.** Relative lifetimes (not to scale) of Raman and photoluminescence (including fluorescence) signals (adapted from ref 25).

The current CMOS SPADs are compact and inexpensive while being able to achieve adequate temporal resolutions (subnanosecond).<sup>37–39</sup> CMOS SPAD detectors have been used to evaluate fluorescence lifetimes.<sup>40</sup> More recently the applicability of CMOS SPADs for fluorescence rejection in Raman spectroscopy in pharmaceuticals has also been shown.<sup>25,36,41</sup>

The aim of this study was to investigate the potential of time-gated Raman spectroscopy for quantitative analysis of fluorescent pharmaceutical solids. A time-gated Raman setup using a fast CMOS SPAD detector<sup>39</sup> was employed for the first time for quantitative analysis of powder mixtures. This instrument allows the separation of the photoluminescence signal from the Raman signal in ambient lighting and enables stronger Raman signal generation compared to traditional instruments.<sup>38,39</sup> The data, with and without prior time-domain selection (based on visual inspection), was analyzed using PLS regression, the most well established multivariate quantitative spectral analysis method in pharmaceuticals. Quantitative analysis was also performed using kernel-based RLS with greedy feature selection, which statistically optimized data use in both the spectral and time domains.

## MATERIALS AND METHODS


**Materials.** Piroxicam (PRX) (Hawkins, USA), a nonsteroidal anti-inflammatory drug, was the fluorescent model compound in this study. PRX has six reported polymorphs ( $\beta$  (I),  $\alpha 1$  and  $\alpha 2$  (both also referred as form II), III, IV, and V)) and one hydrated form (monohydrate, MH).<sup>42–47</sup> Ternary powder mixtures used in this study consisted of the most commonly observed forms:  $\beta$ ,  $\alpha 2$ , and MH.

The PRX was purchased in form  $\beta$ , and this form was used as received. PRX form  $\alpha 2$  was prepared by recrystallization from a saturated solution in absolute ethanol.<sup>46</sup> PRX MH was prepared by recrystallization from saturated aqueous solution.<sup>48</sup> The aqueous solution was heated to 80 °C and the ethanol solution to 70 °C, and the solutions were slowly cooled to room temperature before vacuum filtration.

**Evaluating Polymorph Conversion.** X-ray powder diffractometry (XRPD) analysis was performed using a Bruker D8 Advance diffractometer (Bruker, Germany) with a Cu K $\alpha$  radiation source ( $\lambda = 1.5418$  Å) over a  $2\theta$  range of 5–40°, using

a step size of  $0.01^\circ$ , step time of 0.5 s, voltage of 40 kV, and current of 40 mA. The results were compared to the patterns in the Cambridge Structural Database (CSD). Fourier transform infrared spectroscopy (FTIR) measurements were performed with a Bruker Vertex 70 spectrometer (Bruker Optik, Germany) and an ATR accessory with a single reflection diamond crystal (MIRacle, Pike Technologies, Madison, WI, USA). The obtained spectra were the mean of 64 scans and have a spectral range from  $650$  to  $4000\text{ cm}^{-1}$  with a resolution of  $4\text{ cm}^{-1}$ . The ATR spectra were converted to absorbance spectra with OPUS software (version 5.0, Bruker Optik, Ettlingen, Germany). Differential scanning calorimetry (DSC) was performed with a differential scanning calorimeter (DSC823e, Mettler Toledo AG) in sealed perforated aluminum pans under dry nitrogen purge ( $50\text{ mL/min}$ ) at a heating rate of  $10\text{ }^\circ\text{C/min}$  from  $30$  to  $210\text{ }^\circ\text{C}$ . Particle size and morphology of the PRX solid-state forms were examined by scanning electron microscopy (SEM) with a Quanta 250 FEG (FEI Inc., U.S.). Samples for SEM were mounted on carbon-coated double-sided tape (Agar Scientific, Germany) and sputter-coated with a  $5\text{ nm}$  layer of platinum (Q150T Quomm, Turbo-Pumped Sputter Coater, China).

**Mixture Design.** The powder mixtures were prepared according to a special cubic mixture design (Figure 2).<sup>49</sup> The mass



**Figure 2.** Mixture design employed in the experiments.

ratio of each form was varied between 0, 1:6, 1:3, 2:3, and 1 in the mixtures, and the center point (1:3, 1:3, 1:3) mixture was prepared in triplicate. A ternary mixture design was preferred over a binary mixture design because often more than two solid-state forms are potentially present in a process environment.


The solid-state forms of PRX were carefully mixed using geometric dilution with a card to avoid inducing changes in the solid state.

**Time-Gated Raman Spectroscopy.** Raman spectra of the mixtures of different solid-state forms of PRX were collected with a TimeGated TG532 M1 Raman spectrometer (TimeGate Instruments Oy, Finland) coupled with a BWTek sampling probe with a focal spot size of approximately  $85\text{ }\mu\text{m}$  (Figure 3). The Raman instrument was equipped with a picosecond pulsed laser, CMOS SPAD array detector, and sampling probe. The excitation source was a  $532\text{ nm}$  Nd:YVO microchip pulsed laser. The average power used was  $14\text{ mW}$  ( $2.235\text{ mW}$  after the probe), repetition rate  $40\text{ kHz}$ , pulse width  $150\text{ ps}$ , focus diameter  $50\text{ }\mu\text{m}$ , pulse energy  $0.35\text{ }\mu\text{J}$ , peak power  $2\text{ kW}$ , and maximum irradiance  $28\text{ MW cm}^{-2}$ .

The detector was a  $128 \times (2) \times 4$  CMOS SPAD matrix detector.<sup>39</sup> The internal time histogram of the detector consisted of four bins accumulating single-photon arrivals. Bin 3 provided the strongest Raman signal with the present setup (Figure 3). The signals collected with bin 3 were used for the data analysis. The time-resolved spectral data sets were collected by sequentially moving the gate in  $50\text{ ps}$  steps using the electronic delay generator. Raman spectra with fluorescence rejection and time-resolved fluorescence spectra were acquired simultaneously. The spectra were obtained from the Raman shift range of  $700$ – $1700\text{ cm}^{-1}$  up to  $5.5\text{ ns}$ .

The measurements were conducted in triplicate, with continuous sample rotation, and the focal point was moved between each measurement to acquire a more representative signal over a larger area of the sample. The measurements were carried out at ambient temperature, lighting, and humidity. Cyclohexane was used as a reference standard to monitor wavenumber accuracy. Data acquisition and setup control were performed with the instrument software (TimeGated Model 1).

**Continuous Wave (CW) Raman Spectroscopy.** Raman measurements were executed with a home-built Raman setup in a backscattering geometry using  $532\text{ nm}$  excitation produced with a CW single frequency laser (Alphas, Monolas-532-100-SM). The beam was focused onto the sample and subsequently collected with a  $100\times$  microscope objective (Olympus  $100\times$  with  $0.70\text{ N.A.}$ ). The scattered light was dispersed in a  $0.5\text{ m}$  imaging spectrograph (Acton, SpectraPro 2500i) using a  $600\text{ g/mm}$  grating (resolution:  $\sim 5$ – $6\text{ cm}^{-1}$ ). The signal was detected with EMCCD camera (Andor Newton EM



**Figure 3.** (a) Schematic of the time-gated Raman instrument used for obtaining the Raman spectra and performing fluorescence rejection and (b) basis for bin 3 selection. The four bins collect the scattered photons with different delays and the intensity of the obtained signal varies. Bin 3 provided the strongest signal at the optimal time frame for detection of Raman scattered photons for PRX.



DU971N-BV) using 60  $\mu\text{m}$  slit width. The Rayleigh scattering was attenuated with a notch filter (Semrock). The sample positioning was performed with an XYZ-piezo scanner (Attocube, ANPxyz101) with the smallest step of 100 nm in each direction. The laser power was  $\sim 0.5$  mW, and two 5 s measurements were averaged for each accumulation.

**Partial Least-Squares (PLS).** Part of the fluorescence was rejected from the signal by the time-gated detection system using the data obtained from bin 3 data. Residual photoluminescence (elevated baseline) signal was removed using the software provided with the instrument (TimeGated Model 1). The time frame for analysis was selected manually based on visual appearance of the signal. The location of the Raman peaks in the time domain was found to be at the delay of 0.4–0.8 ns. Baseline correction was performed using adaptive iteratively reweighted penalized least-squares (airPLS) and local minima fitting (Lmin) algorithms. Data from the whole time domain without selecting a specific time frame (0.0–5.5 ns) was processed identically with the selected time frame data for comparison.

PLS is widely used for quantitative Raman spectral analysis of pharmaceutical samples. In general, PLS finds components known as latent factors in variable matrix  $\mathbf{X}$  which best predict the response matrix  $\mathbf{Y}$ . PLS regression searches for a set of factors that simultaneously decompose  $\mathbf{X}$  and  $\mathbf{Y}$  where these factors explain the covariance between the two matrices as much as possible.<sup>50</sup> The spectral data was standard normal variate (SNV) transformed<sup>51</sup> and mean centered (without scaling) prior to PLS analysis. SNV and mean-centering have been shown to be suitable algorithms for quantitative analyses of solid-state mixtures by vibrational spectroscopy.<sup>21</sup> PLS regression<sup>52</sup> for quantitative analysis was carried out with the NIPALS algorithm<sup>17</sup> using SIMCA-P software (version 13.0.3, Umetrics AB, Sweden).

The performance of the model was evaluated using  $R^2\mathbf{X}$ ,  $R^2\mathbf{Y}$ , and the root-mean-square error of cross-validation (RMSECV). RMSECV values were obtained with leave-one-out cross-validation (LOOCV), with the leave-one-out procedure performed with all mixtures except the pure forms (because there is no mixing error associated with the pure forms), where in each CV round all replicates of one mixture are left out. The reported RMSECV values are the average of the root-mean-square error of prediction (RMSEP) values which were obtained for the left-out mixtures for each cross-validation round (eq 1):

$$\text{RMSEP} = \sqrt{\frac{\sum_{i=1}^n (y - \hat{y})^2}{n}} \quad (1)$$

Here,  $y - \hat{y}$  is the predicted residual for each mixture form of an observation.

**Kernel-Based Regularized Squares (RLS).** Part of the fluorescence was rejected from the signal by the time-gated detection system using the data obtained from bin 3 data as in the previous section. To further investigate the quantification potential of the 3D spectra in both the spectral and time dimensions, fast kernel-based RLS analysis with multitarget greedy feature selection was applied. All predictive models were trained with the Python-based machine learning software library RLScore.<sup>19</sup> RLS with a Gaussian kernel was built as the prediction model. Given a training set  $\{(\mathbf{x}_i, y_i)\}_{i=1}^n$  where the feature vector  $\mathbf{x}_i \in \mathbb{R}^p$  and the class labels  $y_i \in \mathbb{R}^q$ , the multivariate RLS formulation finds  $\mathbf{A}$  such that (eq 2):

$$\mathbf{A} = \arg \min_{\mathbf{A}} \frac{1}{n} \|\mathbf{Y} - \mathbf{KA}\|_F^2 + \lambda \text{tr}(\mathbf{A}^T \mathbf{KA}) \quad (2)$$

where  $\mathbf{A}$  is the  $n \times q$  weight matrix,  $\mathbf{Y}$  is the  $n \times q$  label matrix,  $\|\dots\|_F$  is the Frobenius norm of a matrix,  $\mathbf{K}$  is the  $n \times n$  kernel matrix,  $\lambda$  is the regularization parameter, and  $\text{tr}$  is the trace of a matrix. The following Gaussian kernel function was used in the models (eq 3):

$$\mathbf{K}(\mathbf{x}_i, \mathbf{x}_j) = \exp\left(-\frac{\|\mathbf{x}_i - \mathbf{x}_j\|^2}{2\sigma^2}\right) \quad (3)$$

where  $\|\dots\|$  is the  $l_2$  norm and  $\sigma$  is the kernel width parameter.

A kernel-based RLS model was obtained by carrying out the following procedure. A hyperparameter combination consisting of the kernel width parameter,  $\sigma$ , the regularization parameter,  $\lambda$ , and the time interval for averaging with SNV and mean centering, was selected from a three-dimensional grid with LOOCV on a training set. In addition to the hyperparameter values, a multitarget greedy RLS algorithm was built to select a predictive subset of Raman shifts.<sup>18</sup> Greedy RLS starts from the empty set, and on each iteration adds the feature (Raman shift) whose addition provides the best LOOCV performance. To avoid selection bias, the prediction performance of the obtained kernel-based RLS model was estimated with the standard nested cross-validation approach in which the selection procedure described above was separately carried out during each round of an outer cross-validation, and the performance estimate was the average of the prediction errors of these models on the data withheld in the corresponding rounds of the outer cross-validation.<sup>53</sup>

In addition, to ensure that the performance estimate would reflect the real-world conditions under which the model is expected to be used, the fold-partition of the cross-validation was performed similar to PLS analysis as follows. A LOOCV was applied to the PRX mixtures, indicating that every replication of each mixture was simultaneously used as test data and the pure forms were not used for testing.


Given the input vector of a new measurement unseen during the training phase (left-out mixtures for testing), kernel-based RLS makes a prediction of its corresponding output vector. The real-value vectors ( $\mathbf{y} = [\text{predicted value of form } \beta, \text{ predicted value of form } \alpha_2, \text{ predicted value of MH}]$ ) predicted by the kernel-RLS model were postprocessed as follows, with the  $i$ th entry of the vector,  $y_i$ , set as (eq 4):

$$\frac{\max(0, y_i)}{\sum_i \max(0, y_i)} \quad (4)$$

The purpose of this setting was to restrict the mixture proportions between zero and one and prevent impossible predictions. Later, eq 1 was used as described earlier to calculate the RMSECV values of each of the three solid-state forms.

## RESULTS AND DISCUSSION

**Polymorph Conversion.** XRPD, FTIR, and DSC analyses confirmed complete polymorph conversion of form  $\beta$  of PRX (CSD: BIYSEH13)<sup>54</sup> to form  $\alpha_2$  (CSD: BIYSEH06),<sup>46</sup> and MH (CSD: CIDYAP02).<sup>54</sup> No solid-state impurities were detected. SEM images show clear morphological differences between the solid-state forms (Figure S1 (Supporting Information)). Additionally, PCA of the Raman data also showed very clear differences for all the mixtures with no overlap of the sample clusters observed.




**Figure 4.** Raman spectra obtained with (a) the CW Raman setup, (b) the time-gated Raman instrument, presented as sum spectra from 0 to 5.5 ns, and (c) the time-gated Raman instrument, presented as spectra after fluorescence rejection. The Raman intensity scale is the same for each solid-state form but different for each of the three columns for clarity.

**Raman Spectra and Fluorescence Rejection.** Fluorescence, as indicated by the elevated baselines, was observed in both the CW Raman spectra and the time-gated spectra that were the sum of the raw signal recorded over the whole time scale (0–5.5 ns) (Figure 4a,b). Form  $\beta$  fluoresced more strongly than form  $\alpha 2$  and the MH. The baseline increased with increasing Raman shift for all three solid state forms.

Fluorescence rejection with the time-gated data (using bin 3, 0.4–0.8 ns time frame, and residual airPLS and Lmin for baseline correction) resulted in 2D Raman spectra with fluorescence-free baselines (Figure 4c). The characteristic peaks of the solid-state forms of PRX match those previously published.<sup>55</sup> The vibrational modes for piroxicam have previously been predicted and assigned using density functional theory calculations.<sup>56</sup>

The raw 3D spectra recorded with the time-gated instrument (bin 3 data), the subtracted 3D baseline spectra (representing the fluorescence), and the 3D Raman spectra after baseline rejection from PRX form  $\beta$ , form  $\alpha 2$ , and the MH are presented in Figure 5. The 3D data indicates the starting point of the Raman signal immediately after the laser pulse as well as the fluorescence starting-point and the fluorescence tail. Consistent with the spectra in Figure 4b, the 3D spectra also suggest the



**Figure 5.** 3D spectra obtained with time-gated Raman of (a) raw spectrum (form  $\beta$ ), (b) baseline spectrum (form  $\beta$ ), (c) Raman spectrum (form  $\beta$ ), (d) raw spectrum (form  $\alpha 2$ ), (e) baseline spectrum (form  $\alpha 2$ ), (f) Raman spectrum (form  $\alpha 2$ ), (g) raw spectrum (MH), (h) baseline spectrum (MH), and (i) Raman spectrum (MH).

three solid-state forms of PRX fluoresced to varying degrees over the presented Raman shift range, with form  $\beta$  exhibiting the strongest baseline intensity maxima as well as the largest baseline profile change as a function of Raman shift. The 3D plots also reveal the changing baselines over time: a rapid initial increase (at all Raman shifts) is followed by a more gradual decay over several nanoseconds for all three forms. It is important to note that because the presented data are from bin 3 only, the baseline signal cannot be expected to represent the total fluorescence signal over the presented time range, with detected signal intensity biased toward time delays close to the Raman-active time frame. Bin selection for biased detection was appropriate in this case because avoiding fluorescence through instrumental means for improved quantification was one of the aims of the study. Despite this, it is interesting to note that different baseline decay profiles are visible for the three different solid-state forms, supporting previous evidence that not only relative fluorescence intensity (as a function of Raman shift) but also the fluorescence signal lifetime profiles can also be solid-state specific. Differences in such decay profiles have previously been observed using time-gated Raman spectroscopy with the amorphous and  $\gamma$ -crystalline forms of the drug indomethacin.<sup>25</sup>

After subtracting the detected baseline spectra from the raw spectra, very little fluorescence signal was observed and Raman peaks were clearly visible at time delays of less than 1 ns. Overall, the time-gated Raman instrument and with baseline processing enabled robust fluorescence rejection without any requirement for substance specific calibration or suppression methods. This provided a suitable basis for applying chemometric data analysis for quantitative solid-state determination.


**PLS Regression.** The PLS regression used to quantify the mixtures on the basis of the associated Raman spectra using the 0.4–0.8 ns window was successful. Traditional PLS models with four PLS factors resulted in an  $R^2X(\text{cum})$  of 0.997,  $R^2Y(\text{cum})$  of 0.982, and a mean RMSECV of 4.1%, whereas the data from the whole time-domain without selection of a specific time frame (0.0–5.5 ns) resulted in a mean RMSECV of 6.7%,  $R^2X(\text{cum})$  of 0.997, and  $R^2Y(\text{cum})$  of 0.964 with four PLS factors (Table 1).

**Table 1. Data Analysis Performed on the Raman Data with PLS Indicating Time-Frame, Method for Baseline Removal, and RMSECV Values Obtained for Each Crystal Form<sup>a</sup>**

time-frame (ns)	baseline removal	RMSECV form $\beta$ (%)	RMSECV form $\alpha 2$ (%)	RMSECV MH (%)
0.4–0.8	airPLS, Lmin	4.1	4.5	3.8
0.0–5.5	airPLS, Lmin	7.5	6.6	6.0

<sup>a</sup>All spectra were pretreated using SNV transformation and mean centering.

**Kernel-Based Data Analysis.** Iterative optimization of the time frame (an example of the process is presented in Figure 6) with the kernel-based RLS and greedy forward feature selection strongly affected the quantitative performance. Clear differences were observed in the quantitative performance between the optimized and nonoptimized time frames (Table 2). If the full time frame data was used, mean RMSECV values of 6.2%, at best, were obtained. However, when the time frame was optimized, the predictions improved, down to 1.4%. AirPLS (optimized  $\lambda = 10$ ) was found to be most efficient with or without time frame selection. Overall, this result suggests that kernel-based RLS analysis is a valid alternative to the PLS approach in this study for quantitative analysis of time-gated



**Figure 6.** Leave-one-out cross-validation mean squared error (LOOCV-MSE) results from one round of the inner-loop of the kernel-based RLS model, where the model tries to find optimal parameters (time-interval,  $\sigma^2$ ,  $\lambda$ ) based on the LOOCV-MSE. The X-axis represents the number of different time intervals tested during each round of the model construction to find the optimal time interval along with the other optimal model parameters. The time interval corresponding to the lowest LOOCV-MSE was 0.25–0.6 ns in this example.

Raman spectra, as indicated by at best approximately 3-fold lower RMSECV values.

The Gaussian kernel-based RLS model used in this study has the ability to learn target functions from the data capturing the nonlinearity of its features. The kernel-based RLS model accompanied by careful selection of the Raman shifts, time interval, and the models' hyperparameters utilizing a nested cross-validation resulted in improved prediction of the different drug forms in the mixtures. The result of this study supports exploration of the possibilities of efficient optimization of the time frame as well as selection of the best Raman shifts for Raman analysis using kernel based methods and feature selection.

Overall, this study demonstrates that quantitative analysis with time-gated Raman spectroscopy can be suitable for solid-state analysis of photoluminescent pharmaceuticals during drug development and manufacturing. Raman spectroscopy is especially applicable for focusing on the properties of the API in mixtures and pharmaceutical products. This is because the functional moieties present in common APIs typically involve aromatic and  $\pi$ -bonded structures which produce stronger Raman signals than the aliphatic and polar structures typical of common excipients. However, in addition to some APIs, many excipients (e.g., cellulose-based polymers) also fluoresce, which further restricts conventional Raman analysis for the analysis of pharmaceutical processing and dosage forms. An additional advantage of the time-gated measurements is that they can be performed in ambient lighting which facilitates analysis during pharmaceutical processing. These advantages mean that the time-gated Raman spectroscopy approach used in this study has much potential for process monitoring in pharmaceutical manufacturing.

The Raman signals of piroxicam were able to be detected over the fluorescence backgrounds. However, in the case of more extreme or complete Raman signal masking, an instrumental means to avoid fluorescence becomes essential. Time-gated Raman spectroscopy is one such approach.<sup>25</sup>



**Table 2. Data Analysis Performed on the Raman Data with Kernel-Based RLS Indicating Time-Frame, Method for Baseline Removal, Use (+) (or Absence (-)) of Greedy Feature Selection, and RMSECV Values Obtained for Each Crystal Form**

time-frame (ns)	baseline removal	pretreatment	greedy feature selection	RMSECV form $\beta$ (%)	RMSECV form $\alpha 2$ (%)	RMSECV MH (%)
0.35–0.60	airPLS, Lmin	SNV, mean centering	+	2.6	2.5	1.9
0.25–0.60	airPLS	SNV, mean centering	+	1.6	1.2	1.5
0.20–0.65	none	SNV, mean centering	+	2.1	2.2	1.6
0.0–5.5	airPLS, Lmin	SNV, mean centering	–	8.4	6.5	5.9
0.0–5.5	airPLS	SNV, mean centering	–	7.5	6.2	4.9
0.0–5.5	none	SNV, mean centering	–	8.4	7.9	6.8

Even though the PRX Raman bands were still observable without the fluorescence rejection, quantification was improved by the fluorescence rejection. Furthermore, the quantitative analysis approach in this study is applicable to more strongly fluorescing systems, as well as, for example, samples with high water contents, such as proteins and biological and biochemical samples. Altogether, the capability of the time-resolved Raman and fluorescence measurements with a CMOS SPAD detector for quantitative analysis shows promise in diverse areas, including fundamental chemical research, the pharmaceutical setting, process analytical technology (PAT), and the life sciences.

## CONCLUSIONS

This study demonstrates that time-gated Raman spectroscopy is a useful tool for quantifying mixtures of fluorescent materials when conventional Raman spectroscopy could fail. PLS analysis of the time-gated spectra allowed quantitative analysis and demonstrated the benefit of time-domain selection. In this case, statistical optimization of model parameters using kernel-based RLS further improved the quantitative results. Overall, the time-gated Raman spectroscopy approach employed shows potential for relatively routine quantitative solid-state analysis of photoluminescent pharmaceuticals during drug development and manufacturing.

## ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.analchem.8b00298.

SEM images of the PRX crystal forms used in this study (PDF)

## AUTHOR INFORMATION

### Corresponding Author

\*E-mail: clare.strachan@helsinki.fi.

### ORCID

Tiina Lipiäinen: 0000-0002-4460-3079

Jenni Pessi: 0000-0002-8723-6715

Juha Koivistoinen: 0000-0002-7304-005X

Clare J. Strachan: 0000-0003-3134-8918

### Author Contributions

<sup>†</sup>T.L. and J.P. contributed equally.

### Notes

The authors declare the following competing financial interest(s): Lauri Kurki and Mari Tenhunen are affiliated with the company that commercialized the CMOS SPAD detector technology used in this research.

## ACKNOWLEDGMENTS

Tekes, the Finnish Funding Agency for Innovation (project no. 1245/31/2015), the University of Helsinki (three-year grant, project no. 490146), and the Academy of Finland (project nos. 289398, 311273, and 313266) are acknowledged for funding the work. T. Lipiäinen acknowledges the Finnish Cultural Foundation (Elli Turunen Fund). J. Pessi acknowledges the Drug Research Doctoral Program of the Faculty of Pharmacy, University of Helsinki. The authors thank the Electron Microscopy Unit of Institute of Biotechnology, University of Helsinki, for providing laboratory facilities.

## REFERENCES

- (1) Gupta, R. B.; Kompella, U. B. *Nanoparticle Technology for Drug Delivery*; CRC Press: New York, 2006.
- (2) Vippagunta, S. R.; Brittain, H. G.; Grant, D. J. *Adv. Drug Delivery Rev.* **2001**, *48*, 3–26.
- (3) Halebian, J.; McCrone, W. J. *Pharm. Sci.* **1969**, *58*, 911–929.
- (4) Vankeirsbilck, T.; Vercauteren, A.; Baeyens, W.; Van der Weken, G.; Verpoort, F.; Vergote, G.; Remon, J. P. *TrAC, Trends Anal. Chem.* **2002**, *21*, 869–877.
- (5) Brittain, H. G. *J. Pharm. Sci.* **1997**, *86*, 405–412.
- (6) Wartewig, S.; Neubert, R. H. *Adv. Drug Delivery Rev.* **2005**, *57*, 1144–1170.
- (7) Strachan, C. J.; Pratiwi, D.; Gordon, K. C.; Rades, T. *J. Raman Spectrosc.* **2004**, *35*, 347–352.
- (8) Das, R. S.; Agrawal, Y. *Vib. Spectrosc.* **2011**, *57*, 163–176.
- (9) Tian, F.; Zhang, F.; Sandler, N.; Gordon, K.; McGovern, C.; Strachan, C.; Saville, D.; Rades, T. *Eur. J. Pharm. Biopharm.* **2007**, *66*, 466–474.
- (10) Jestel, N. L. In *Process Analytical Technology Spectroscopic Tools and Implementation Strategies for the Chemical and Pharmaceutical Industries*; Bakeev, K. A., Ed.; Blackwell Publishing Ltd.: Oxford, UK, 2005; pp 133–169.
- (11) Raman, C. V.; Krishnan, K. S. *Nature* **1928**, *121*, 501–502.
- (12) McCreery, R. L. In *Raman Spectroscopy for Chemical Analysis*; Wiley: Hoboken, NJ, 2000; pp 15–34.
- (13) Aaltonen, J.; Gordon, K. C.; Strachan, C. J.; Rades, T. *Int. J. Pharm.* **2008**, *364*, 159–169.
- (14) Pelletier, M. *Appl. Spectrosc.* **2003**, *57*, 20A–42A.
- (15) Strachan, C. J.; Rades, T.; Gordon, K. C.; Rantanen, J. *J. Pharm. Pharmacol.* **2007**, *59*, 179–192.
- (16) Eriksson, L.; Byrne, T.; Johansson, E.; Trygg, J.; Vikström, C. *Multi- and Megavariate Data Analysis—Basic Principles and Applications*, 3rd ed.; MKS Umetrics AB: Malmö, Sweden, 2013.
- (17) Wold, S.; Sjöström, M.; Eriksson, L. *Chemom. Intell. Lab. Syst.* **2001**, *58*, 109–130.
- (18) Naula, P.; Airola, A.; Salakoski, T.; Pahikkala, T. *Pattern Recogn. Lett.* **2014**, *40*, 56–65.
- (19) Pahikkala, T.; Airola, A. *J. Mach. Learn. Res.* **2016**, *17*, 1–5.
- (20) Frank, I. E.; Friedman, J. H. *Technometrics* **1993**, *35*, 109–135.
- (21) Heinz, A.; Savolainen, M.; Rades, T.; Strachan, C. J. *Eur. J. Pharm. Sci.* **2007**, *32*, 182–192.
- (22) Chen, Z.-P.; Li, L.-M.; Jin, J.-W.; Nordon, A.; Littlejohn, D.; Yang, J.; Zhang, J.; Yu, R.-Q. *Anal. Chem.* **2012**, *84*, 4088–4094.

- (23) Fishburn, M. W. Fundamentals of CMOS single-photon avalanche diodes. Doctoral Thesis. Delft University of Technology, Delft, The Netherlands, 2012.
- (24) Patounakis, G.; Shepard, K. L.; Levicky, R. *IEEE J. Solid-State Circuits* **2006**, *41*, 2521–2530.
- (25) Rojalín, T.; Kurki, L.; Laaksonen, T.; Viitala, T.; Kostamovaara, J.; Gordon, K. C.; Galvis, L.; Wachsmann-Hogiu, S.; Strachan, C. J.; Yliperttula, M. *Anal. Bioanal. Chem.* **2016**, *408*, 761–774.
- (26) Iams, H.; Salzberg, B. *Proc. IRE* **1935**, *23*, 55–64.
- (27) Van Duyne, R. P.; Jeanmaire, D. L.; Shriver, D. *Anal. Chem.* **1974**, *46*, 213–222.
- (28) Matousek, P.; Towrie, M.; Parker, A. J. *Raman Spectrosc.* **2002**, *33*, 238–242.
- (29) Matousek, P.; Towrie, M.; Ma, C.; Kwok, W.; Phillips, D.; Toner, W.; Parker, A. J. *Raman Spectrosc.* **2001**, *32*, 983–988.
- (30) Efremov, E. V.; Buijs, J. B.; Gooijer, C.; Ariese, F. *Appl. Spectrosc.* **2007**, *61*, 571–578.
- (31) Blakesley, J.; See, P.; Shields, A.; Kardynał, B.; Atkinson, P.; Farrer, I.; Ritchie, D. *Phys. Rev. Lett.* **2005**, *94*, 067401.
- (32) Kabuss, J.; Werner, S.; Hoffmann, A.; Hildebrandt, P.; Knorr, A.; Richter, M. *Phys. Rev. B: Condens. Matter Mater. Phys.* **2010**, *81*, 075314.
- (33) Stoppa, D.; Pancheri, L.; Scandiuozzo, M.; Gonzo, L.; Dalla Betta, G.-F.; Simoni, A. *IEEE Trans. Circuits Syst. I* **2007**, *54*, 4–12.
- (34) Stoppa, D.; Mosconi, D.; Pancheri, L.; Gonzo, L. *IEEE Sens. J.* **2009**, *9*, 1084–1090.
- (35) Rochas, A.; Gani, M.; Furrer, B.; Besse, P.; Popovic, R.; Ribordy, G.; Gisin, N. *Rev. Sci. Instrum.* **2003**, *74*, 3263–3270.
- (36) Nissinen, L.; Nissinen, J.; Keränen, P.; Kostamovaara, J. *Sens. Actuators, B* **2017**, *241*, 1145–1152.
- (37) Mosconi, D.; Stoppa, D.; Pancheri, L.; Gonzo, L.; Simoni, A. CMOS single-photon avalanche diode array for time-resolved fluorescence detection. *2006 IEEE Proc. Eur. Solid-State Circuits Conf.*, 2006; pp 564–567.
- (38) Nissinen, L.; Nissinen, J.; Keränen, P.; Lämsman, A.-K.; Holma, J.; Kostamovaara, J. *IEEE Sens. J.* **2015**, *15*, 1358–1365.
- (39) Kostamovaara, J.; Tenhunen, J.; Kögler, M.; Nissinen, L.; Nissinen, J.; Keränen, P. *Opt. Express* **2013**, *21*, 31632–31645.
- (40) Schwartz, D. E.; Charbon, E.; Shepard, K. L. A single-photon avalanche diode imager for fluorescence lifetime applications. *2007 IEEE Symposium on VLSI Circuits*, 2007; pp 144–145.
- (41) Maruyama, Y.; Blacksborg, J.; Charbon, E. *IEEE J. Solid-State Circuits* **2014**, *49*, 179–189.
- (42) Lavrič, Z.; Pirnat, J.; Lužnik, J.; Puc, U.; Trontelj, Z.; Srčič, S. *J. Pharm. Sci.* **2015**, *104*, 1909–1918.
- (43) Naelapää, K.; van de Streek, J.; Rantanen, J.; Bond, A. D. *J. Pharm. Sci.* **2012**, *101*, 4214–4219.
- (44) Sheth, A. R.; Bates, S.; Muller, F. X.; Grant, D. *Cryst. Growth Des.* **2004**, *4*, 1091–1098.
- (45) Upadhyay, P. P.; Bond, A. D. *CrystEngComm* **2015**, *17*, 5266–5272.
- (46) Vrečer, F.; Vrbinc, M.; Meden, A. *Int. J. Pharm.* **2003**, *256*, 3–15.
- (47) Thomas, L. H.; Wales, C.; Wilson, C. C. *Chem. Commun.* **2016**, *52*, 7372–7375.
- (48) Kogermann, K.; Aaltonen, J.; Strachan, C. J.; Pöllänen, K.; Heinämäki, J.; Yliruusi, J.; Rantanen, J. *J. Pharm. Sci.* **2008**, *97*, 4983–4999.
- (49) Eriksson, L.; Johansson, E.; Wikström, C. *Chemom. Intell. Lab. Syst.* **1998**, *43*, 1–24.
- (50) Abdi, H. Partial least squares (PLS-regression). In *Encyclopedia for Social Science Research Methods*; Lewis-Beck, M., Bryman, A., Futing, T., Eds.; SAGE: Thousand Oaks, CA, 2003; pp 792–795.
- (51) Barnes, R.; Dhanoa, M. S.; Lister, S. *J. Appl. Spectrosc.* **1989**, *43*, 772–777.
- (52) Martens, H.; Naes, T. *Multivariate Calibration*; John Wiley & Sons: New York, 1992.
- (53) Varma, S.; Simon, R. *BMC Bioinf.* **2006**, *7*, 91.
- (54) Shi, X.; El Hassan, N.; Ikni, A.; Li, W.; Guiblin, N.; Spasojević de-Biré, A. S.; Ghermani, N. *CrystEngComm* **2016**, *18*, 3289–3299.
- (55) Redenti, E.; Zanol, M.; Ventura, P.; Fronza, G.; Comotti, A.; Taddei, P.; Bertoluzza, A. *Biospectroscopy* **1999**, *5*, 243–251.
- (56) Suresh, S.; Gunasekaran, S.; Srinivasan, S. *Spectrochim. Acta, Part A* **2015**, *138*, 447–459.